Back to search

Peptide record

TPDB42905

9S1R Anticancer standard
10 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42905
9S1R
Anticancer
Cancer-related peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF
standard
No
A 10-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
Sequence
RRRRRWCMNW
Physicochemical Analysis
C64H102N28O12S2
ADEQGHILKFPSTYV
R
1519.81
12.58
5
0
3
+5
0.30
-2.340
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
11000
723.77
2
Residue Composition
number
0
A
5
R
1
N
0
D
1
C
0
E
0
Q
0
G
0
H
0
I
0
L
0
K
1
M
0
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 5 N: 1 D: 0 C: 1 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 1 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
10
C64H102N28O12S2
1519.81
12.58
+5
0.30
-2.340
Free
L
Linear
Free
Anticancer
Nullomer derived anticancer peptides (NulloPs):
Evidence Records 13 records
Evidence 1 Activity

Activity

IC50
IC50=26 µM
Anticancer
26 µM

Target

Prostate Cancer
LNCaP
Prostate

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=9 µM
Anticancer
9 µM

Target

Prostate Cancer
LNCaP
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

IC50
IC50=8 µM
Anticancer
8 µM

Target

Prostate Cancer
LNCaP
Prostate

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

IC50
IC50=18 µM
Anticancer
18 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

IC50
IC50=12 µM
Anticancer
12 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

IC50
IC50=10 µM
Anticancer
10 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

IC50
IC50=38 µM
Anticancer
38 µM

Target

Lymphoma Cancer
HUT-102
Blood

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 8 Activity

Activity

IC50
IC50=43 µM
Anticancer
43 µM

Target

Lymphoma Cancer
HUT-102
Blood

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 9 Activity

Activity

IC50
IC50=43 µM
Anticancer
43 µM

Target

Lymphoma Cancer
HUT-102
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 10 Activity

Activity

IC50
IC50=45 µM
Anticancer
45 µM

Target

Lymphoma Cancer
HUT-102
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 11 Activity

Activity

IC50
IC50=36 µM
Anticancer
36 µM

Target

Lymphoma Cancer
HUT-102
Blood

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 12 Activity

Activity

IC50
IC50=26 µM
Anticancer
26 µM

Target

Tumor
J774A.1
Blood

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 13 Activity

Activity

IC50
IC50=17 µM
Anticancer
17 µM

Target

Tumor
J774A.1
Blood

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012